Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin L Jones

Showing results (101-110 of 393) with videos related to

Pageof 40
Sort By:
The Lancet. Oncology|March 22, 2015
Redefining the standard of care in metastatic leiomyosarcomaJonathan Noujaim, Winette T A van der Graaf, Robin L Jones
Expert Opinion on Pharmacotherapy|June 16, 2023
Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?Magdalena Meissner, Andrea Napolitano, Khin Thway, et al.
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedsideDavid Olmos, Daniel S W Tan, Robin L Jones, et al.
Future Oncology (London, England)|May 12, 2018
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labelingPeter Reichardt, Marie-Dominique Tabone, Jaume Mora, et al.
Rare Tumors|May 2, 2017
Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic SiteKhin Thway, Jonathan Noujaim, D Michael Thomas, et al.
The Lancet. Oncology|September 1, 2004
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicinRobin L Jones, Gerald J Berry, Robert D Rubens, et al.
Marine Drugs|February 17, 2015
Trabectedin in soft tissue sarcomasBradley J Petek, Elizabeth T Loggers, Seth M Pollack, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2009
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosisAnastasia Constantinidou, Robin L Jones, Michelle Scurr, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Olaratumab in soft tissue sarcoma - Current status and future perspectivesGeorgios Antoniou, Alexander T J Lee, Paul H Huang, et al.
International Journal of Surgical Pathology|July 4, 2020
<i>EWSR1-SMAD3</i>-Positive Fibroblastic TumorOliver Foot, Magnus Hallin, Robin L Jones, et al.
Pageof 40

Showing results (101-110 of 393) with videos related to

Sort By:
Pageof 40
The Lancet. Oncology|March 22, 2015
Redefining the standard of care in metastatic leiomyosarcomaJonathan Noujaim, Winette T A van der Graaf, Robin L Jones
Expert Opinion on Pharmacotherapy|June 16, 2023
Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?Magdalena Meissner, Andrea Napolitano, Khin Thway, et al.
Cancer Journal (Sudbury, Mass.)|June 8, 2010
Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedsideDavid Olmos, Daniel S W Tan, Robin L Jones, et al.
Future Oncology (London, England)|May 12, 2018
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labelingPeter Reichardt, Marie-Dominique Tabone, Jaume Mora, et al.
Rare Tumors|May 2, 2017
Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic SiteKhin Thway, Jonathan Noujaim, D Michael Thomas, et al.
The Lancet. Oncology|September 1, 2004
Clinical and pathological absence of cardiotoxicity after liposomal doxorubicinRobin L Jones, Gerald J Berry, Robert D Rubens, et al.
Marine Drugs|February 17, 2015
Trabectedin in soft tissue sarcomasBradley J Petek, Elizabeth T Loggers, Seth M Pollack, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2009
Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosisAnastasia Constantinidou, Robin L Jones, Michelle Scurr, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2018
Olaratumab in soft tissue sarcoma - Current status and future perspectivesGeorgios Antoniou, Alexander T J Lee, Paul H Huang, et al.
International Journal of Surgical Pathology|July 4, 2020
<i>EWSR1-SMAD3</i>-Positive Fibroblastic TumorOliver Foot, Magnus Hallin, Robin L Jones, et al.
Pageof 40